Three Swiss Start-ups were selected among the top 25 award winners of the European Venture contest (EVC). Fastree3D, CALCISCON, Gene Predictis were selected out of the 1000 start-ups that applied for the EVC.
The European Venture Contest is an annual event that finds, evaluates and awards the most promising entrepreneurs in the high technology sector by providing access to top‐level international partners, advisors and financiers. The Contest this year gathered over 1000 companies and 600 venture capitalist and corporate investors from all over Europe.
100 promising companies were filtered out of over 1000 applications that were submitted and 600 pitches were held throughout Europe Unlimited’s 2015 calendar. The 100 presenting companies at the European Venture Summit were invited as the top rated companies of the European Venture Contest.These 100 companies were reviewed online and onsite by investors and the investor jury on 7 criteria. The Top 25 winners, among which are three Swiss start-ups got the highest review ratings following the online screening and onsite pitches.
The three selected Swiss start-ups among the 25 winners were in two of the three awarded categories; ICT and Life sciences. These include;
Fastree3D
Fastree3D develops 3D imaging sensors that enable vehicles and machines to recognize and locate fast-moving objects in three dimensions in real-time, enabling safe and intelligent actions such as driving assistance or autonomous navigation.
CALCISCON AG
The Bern-based startup is a biotech company providing a novel blood test for the assessment of calcification propensity and improved cardiovascular risk management. With this technology, the company aims at becoming a leader in the early detection of patients at an elevated risk of calcification.
Gene Predictis
Gene Predictis develops and commercializes innovative, clinically relevant diagnostic tools based on genetics that allow tailored treatments for patients. Precisely, the products enable to improve drug treatment efficacy and/or significantly reduce harmful side effects resulting from adverse drug reactions, thereby contributing to reduce costs for the health care system. The company was founded in 2004 and has been financed so far by founders’ assets and company’s sales. Gene Predictis has acquired significant experience in its field and developed a highly differentiated product portfolio in niche markets, with a cost-effective structure and its own laboratory facilities.
(SK / RAN)
0Comments
Please login or sign up to comment.
Commenting guidelines